Clinical Research Directory
Browse clinical research sites, groups, and studies.
Randomized Control Trial of Sleeve Gastrectomy with Tirzepatide in Maximizing Weight Loss
Sponsor: Nicholas Skertich
Summary
This study examines whether adding tirzepatide-a medication that helps with weight loss-after sleeve gastrectomy surgery can help people lose more weight after the surgery; better improve conditions like Type 2 diabetes, high blood pressure, high cholesterol, and sleep apnea after surgery and; whether this causes more complications or side effects compared to surgery alone.
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
42
Start Date
2025-03-10
Completion Date
2028-03
Last Updated
2025-03-14
Healthy Volunteers
No
Interventions
Mounjaro
In this study, the intervention group (n=21) are patients who will undergo sleeve gastrectomy and receive tirzepatide after surgery. Patients who were selected in this arm will undergo a 4-week dose escalation period. Starting at 6 months they will receive weekly 2.5mg doses (for 4 weeks). Afterwards, they will receive weekly 5mg doses. They will maintain this dose until 12 months after surgery.
Sleeve Gastrectomy
Subjects in both the interventional group (n=21) and the control group (n=21) will undergo sleeve gastrectomy.
Locations (1)
Rush University Medical Center
Chicago, Illinois, United States